semaglutide shortage november 2025 news The Wegovy Continues, Leaving Patients On the Weight Loss Drug in Limbo FDA: Novo Nordisk's Ozempic and

In total, 12,004 patients using GLP-1 receptor agonists were compared with 15,221 using SGLT-2 inhibitors and a further 11,964 GLP-1 users were compared with 11,233 DPP-4 inhibitor users between January 2019 and September 2024

Reporting Side Effects Through the MHRA Yellow Card Scheme Suspected side effects from retatrutide used outside a clinical trial should be reported via the MHRA Yellow Card Scheme

The survey is available online (at Briefly, the first section of the survey includes questions on patient demographics, diagnoses, illness duration and severity, symptoms, comorbidities, and lab tests, while the remaining sections focus on treatments

pre-load adjusted contractility, dP / dt max /EDV